Niemann-Pick Type C Disease: Clinical Trials

3 trials for Niemann-Pick Type C Disease, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 recruiting, 1 terminated. 3 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 33Recruiting 2, Terminated 1

Follow Niemann-Pick Type C Disease: new trials by email Literature Review of Niemann-Pick Type C Disease trials Research Report on Niemann-Pick Type C Disease

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease, GM1 Gangliosidosis or GM2 Gangliosidosis
AZ-3102, Placebo - Niemann-Pick Type C Disease, GM1 Gangliosidosis
Phase 3RecruitingAzafaros B.V.1472025-06-302026-10-27
A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease (NPC)
Nizubaglustat, Placebo - Niemann-Pick Type C Disease
Phase 3RecruitingAzafaros B.V.722025-06-302026-10-28
Niemann-Pick Type C Treatment With Adrabetadex for Symptoms of Brain and Nervous System
Adrabetadex - Niemann-Pick Type C Disease
Phase 3TerminatedMandos LLC272018-06-182024-01-17

Narrower conditions

Niemann-Pick Disease, Type C (3)  ·  Gangliosidoses, GM2 (1)  ·  Gangliosidosis, GM1 (1)

Broader conditions

Brain Diseases (3)  ·  Brain Diseases, Metabolic (3)  ·  Brain Diseases, Metabolic, Inborn (3)  ·  Central Nervous System Diseases (3)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (3)  ·  Genetic Diseases, Inborn (3)  ·  Hemic and Lymphatic Diseases (3)  ·  Histiocytosis (3)  ·  Histiocytosis, Non-Langerhans-Cell (3)  ·  Lipid Metabolism Disorders (3)  ·  Lipid Metabolism, Inborn Errors (3)  ·  Lipidoses (3)  ·  Lymphatic Diseases (3)  ·  Lysosomal Storage Diseases (3)  ·  Lysosomal Storage Diseases, Nervous System (3)

Interventions

2-Hydroxypropyl-beta-cyclodextrin (1)

Sponsors

Azafaros B.V. (2)  ·  Mandos LLC (1)

Countries

United States (3)  ·  Argentina (2)  ·  Australia (2)  ·  Brazil (2)  ·  Canada (2)  ·  Germany (2)  ·  India (2)  ·  Italy (2)  ·  Mexico (2)  ·  Pakistan (2)  ·  Portugal (2)  ·  Spain (2)  ·  Switzerland (2)  ·  Turkey (Türkiye) (2)  ·  United Kingdom (2)